Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Legendary Biotech Releases Updated Company Profile
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Legend Biotech Announces Presentation at the American Society of Hematology (ASH) 2023
Legend Biotech | 6-K: Legend Biotech Announces Exclusive Global License Agreement for Certain CAR-T Therapies Targeting DLL3
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Legend Biotech | 6-K: Poll Results of 2023 Annual Meeting of Shareholders
Legend Biotech | 6-K: Notice of Annual General Meeting
Legend Biotech | 6-K: Legend Biotech Will Hold Its Annual General Meeting of Shareholders on September 21, 2023
Legend Biotech | 6-K: Legend Biotech Reports Second Quarter 2023 Results and Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2023 and for the six months ended June 30, 2023 and 2022
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
No Data